Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Benzphetamine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 known ✓ | P23975 | 1/20 | 0.96 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.96 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.96 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.96 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.96 |
| ▸ | HTR2A | P28223 | 1/20 | 0.96 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.96 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.96 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.96 |
| ▸ | SIGMAR1 | Q99720 | 5/20 | 0.65 |
| ▸ | MAOB | P27338 | 6/20 | 0.64 |
| ▸ | MAOA | P21397 | 4/20 | 0.64 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.64 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.64 |
| ▸ | TSHR | P16473 | 3/20 | 0.61 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.61 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.61 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.61 |
| ▸ | SNCA | P37840 | 1/20 | 0.61 |
| ▸ | PKM | P14618 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Benzphetamine SCHEMBL28360250 | 1.00 | ADRA2B (0.96) | ADRA2BADRA2CADRA1AOPRK1SLC6A2 | |
| Benzphetamine SCHEMBL265137 | 1.00 | ADRA2B (0.96) | ADRA2BADRA2CADRA1AOPRK1SLC6A2 | |
| Benzphetamine SCHEMBL6272098 | 1.00 | ADRA2B (0.96) | ADRA2BADRA2CADRA1AOPRK1SLC6A2 | |
| Benzphetamine SCHEMBL49120 | 0.98 | ADRA2B (1.00) | ADRA2BADRA2CADRA1AOPRK1SLC6A2 | |
| Benzphetamine SCHEMBL19285634 | 0.98 | ADRA2B (1.00) | ADRA2BADRA2CADRA1AOPRK1SLC6A2 | |
| Benzphetamine SCHEMBL678807 | 0.98 | ADRA2B (1.00) | ADRA2BADRA2CADRA1AOPRK1SLC6A2 | |
| Benzphetamine SCHEMBL4329836 | 0.94 | ADRA2B (0.92) | ADRA2BADRA2CADRA1AOPRK1SLC6A2 | |
| Benzphetamine SCHEMBL15388333 | 0.91 | ADRA2B (0.86) | ADRA2BADRA2CADRA1AOPRK1SLC6A2 | |
| Hydrochloric Acid SCHEMBL9125055 | 0.82 | ADRA2B (0.66) | ADRA2BADRA2CADRA1AOPRK1SLC6A2 | |
| SCHEMBL12648381 | 0.82 | SLC6A2 (0.71) | ADRA2BADRA2CADRA1AOPRK1SLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 4895 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4654966-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF OBESITY AND DISEASES ASSOCIATED WITH FAT CELL ENLARGEMENT | MELLICELL, INC. (US) | 2025-12-03 | — | — | EP | claimed |
| WO-2025137653-A1 | METHODS AND COMPOSITIONS OF POLYCYCLIC AND A DUAL ACTING NITROXIDE COMPOUNDS FOR TREATMENT OF FAT CELL ASSOCIATED DISEASES | MELLICELL, INC. (US) | 2025-06-26 | — | — | WO | claimed |
| US-20250032503-A1 | USE OF APREPITANT FOR TREATING ALZHEIMER'S DISEASE | HOTH THERAPEUTICS, INC. | 2025-01-30 | — | — | US | claimed |
| US-20240282425-A1 | AUTHENTICATION METHODS AND SYSTEMS FOR DISPENSED PRESCRIPTIONS | LOW GORDON KEITH (US) | 2024-08-22 | — | — | US | claimed |
| WO-2024159211-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF OBESITY AND DISEASES ASSOCIATED WITH FAT CELL ENLARGEMENT | MELLICELL, INC. (US) | 2024-08-02 | — | — | WO | claimed |
| EP-4297868-A1 | USE OF APREPITANT FOR TREATING ALZHEIMER'S DISEASE | Hoth Therapeutics, Inc. (US) | 2024-01-03 | — | — | EP | claimed |
| CN-110668952-B | Preparation method of benzphetamine hydrochloride | 安徽贝克制药股份有限公司 | 2023-06-27 | — | — | CN | claimed |
| CN-110655466-B | Preparation method of benzphetamine hydrochloride | 安徽贝克制药股份有限公司 | 2023-02-24 | — | — | CN | claimed |
| WO-2022182658-A1 | USE OF APREPITANT FOR TREATING ALZHEIMER'S DISEASE | HOTH THERAPEUTICS, INC. (US) | 2022-09-01 | — | — | WO | claimed |
| CN-114053207-A | Sustained-release pharmaceutical composition and preparation method thereof | 常州恒邦药业有限公司 | 2022-02-18 | — | — | CN | claimed |
| EP-0652774-B1 | PHARMACEUTICAL COMPOSITION FOR TOPICAL USE CONTAINING A CROSSLINKED CATIONIC POLYMER AND AN ALKOXYLATED ETHER | PROCTER & GAMBLE (US) | 1997-05-07 | — | — | EP | claimed |
| US-5614178-A | TRANSDERMAL | THE PROCTER & GAMBLE COMPANY (US) | 1997-03-25 | — | — | US | claimed |
| EP-0652774-A1 | PHARMACEUTICAL COMPOSITION FOR TOPICAL USE CONTAINING A CROSSLINKED CATIONIC POLYMER AND AN ALKOXYLATED ETHER. | PROCTER & GAMBLE (US) | 1995-05-17 | — | — | EP | claimed |
| EP-0608322-A1 | ENHANCED SKIN PENETRATION SYSTEM FOR IMPROVED TOPICAL DELIVERY OF DRUGS | RICHARDSON-VICKS, INC. (US) | 1994-08-03 | — | — | EP | claimed |
| WO-1994002176-A1 | PHARMACEUTICAL COMPOSITION FOR TOPICAL USE CONTAINING A CROSSLINKED CATIONIC POLYMER AND AN ALKOXYLATED ETHER | THE PROCTER & GAMBLE COMPANY (US) | 1994-02-03 | — | — | WO | claimed |
| CN-1072863-A | Be used to improve the dermal osmosis system of the reinforcement of medicine localized delivery | RICHARDSON VICKS INC (US) | 1993-06-09 | — | — | CN | claimed |
| CN-1072602-A | Improve the enhanced dermal osmosis system of the local conveying of medicine | RICHARDSON VICKS INC (US) | 1993-06-02 | — | — | CN | claimed |
| WO-1993007903-A1 | ENHANCED SKIN PENETRATION SYSTEM FOR IMPROVED TOPICAL DELIVERY OF DRUGS | RICHARDSON-VICKS, INC. (US) | 1993-04-29 | — | — | WO | claimed |
| US-5023088-A | Drug delivery dispenser | ALZA CORPORATION (US) | 1991-06-11 | — | — | US | claimed |
| US-3968245-A | Sympathomimetic topical and percutaneous administration with halogenated promoters | ALZA CORPORATION (US) | 1976-07-06 | — | — | US | claimed |